CRISPR-Cas9 Technology Used to Understand Glioblastoma

The most common type of primary malignant brain tumor in adults, glioblastoma is also one of the deadliest cancers, with a median survival rate of 10 to 14 months. Until recently, understanding of glioblastoma growth and survival was limited. Now, scientists report that "reverse engineering" glioblastoma stem cells gene by gene using CRISPR-Cas9 unveiled multiple therapeutic targets to combat treatment resistance, including the SOX transcription factor family. "We think that, in one big experime...
Continue reading

In Ependymoma, Post-Surgery Radiation Increases Survival

​ A phase 2 clinical trial reports that for children with ependymoma, the third most common pediatric brain tumor, radiation immediately following surgical resection substantially increases survival, even improving outcomes for children under the age of three. "Historically, children under the age of three with ependymoma have a worse prognosis than older children," said Thomas E. Merchant, DO, PhD, Chair of the Department of Radiation Oncology at St. Jude Children's Research Hospital and first ...
Continue reading

New Technology Characterizes Rare Pediatric Cancer

In a new study conducted by researchers at Princeton University in collaboration with Michigan State University and the University of Oslo, a unified computational framework called Unveiling RNA Sample Annotation for Human Diseases (URSA HD ) analyzed hundreds of molecular patterns of various diseases instantaneously, detecting genes behind a wide variety of diseases. Four of the genes that the researchers identified were linked to neuroblastoma, a rare form of cancer that predominantly affects ...
Continue reading

New Therapeutic Target for Melanoma Brain Metastases

Almost half of patients with malignant melanoma develop metastases in different organs, with 60% of metastases spreading to the brain. Once the cancer metastasizes, the 5-year survival rate plummets to 5% to 19%. Metastasized malignancies are resistant to current immunotherapies and targeted therapies; however, researchers at the University of Texas MD Anderson Cancer Center discovered that oxidative phosphorylation (OXPHOS) can be a potential treatment target. "Brain metastases are increasingly...
Continue reading

Glioblastoma: New First-Line Treatment Regimen Provides Hope

​ A phase 3 clinical trial has shown that a regimen consisting of lomustine and temozolomide in combination with radiotherapy can improve survival for patients with previously untreated glioblastoma with MGMT promoter methylation. Glioblastoma, the most common form of primary brain tumor, is highly aggressive and extremely deadly, with a five-year survival rate of only 5.6%. Standard treatment is radiotherapy followed by chemotherapy with temozolomide, an alkylating agent (a drug that interferes...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.